Atreca will lead clinical development, regulatory and commercialization activities for this program, and the second potential joint program would be advanced by Xencor.

Source: https://www.marketscreener.com/quote/stock/ATRECA-INC-59968119/news/Atreca-and-Xencor-to-Develop-T-Cell-Engaging-Bispecific-Antibody-Directed-Against-Novel-Solid-Tumor-42909478/?utm_medium=RSS&utm_content=20230206

Xencor had a negative return on equity of 7.47% and a negative net margin of 33.53%.

Source: https://www.americanbankingnews.com/2023/03/15/celia-eckert-sells-711-shares-of-xencor-inc-nasdaqxncr-stock.html

Xencor had a return on equity of 4.04% and a net margin of 10.07%.

Source: https://www.etfdailynews.com/2023/01/15/assenagon-asset-management-s-a-decreases-stock-position-in-xencor-inc-nasdaqxncr/